Menu
Not yet recruiting NCT07028541

RemeOs™ DrillPin for Fixation of Distal Radius Fractures in Children

No phase Interventional Fracture Fixation, Internal Distal Radius Fracture

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Magnesium-based bioresorbable DrillPin for fixation of distal radius fractures in children.
Who it may be relevant to
Registry conditions: Fracture Fixation, Internal, Distal Radius Fracture. Basic parameters: 5 years — 13 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

To Evaluate the Feasibility of the Clinical Application of Mg-based RemeOs™ DrillPin for Fixation of Fractures of the Distal Radius in Children From the Age of Over 5 and Under 14.

Overview

This is a pre-market, single-arm, open-label, monocenter clinical investigation evaluating the safety and performance of the magnesium (Mg)-based bioresorbable RemeOs™ DrillPin for surgical fixation of distal radius fractures in pediatric patients. The study will enroll 20 children aged over 5 and under 14 years to assess implantation success, early safety outcomes, and long-term effects on growth and bone healing.

Detailed description

This single-arm, open-label, monocenter clinical investigation is conducted in accordance with ISO 14155 to evaluate the safety and performance of the RemeOs™ DrillPin (a bioresorbable magnesium-based implant) used for internal fixation of distal radius fractures in pediatric patients.

Eligible participants are children aged over 5 and under 14 years who require surgical fixation of a distal radius fracture. The RemeOs™ DrillPin is designed to offer stable fracture fixation while gradually resorbing in the body, potentially reducing the need for implant removal.

Primary objectives include evaluating implantation success-defined by low pain levels (FACES® Pain Rating Scale score \<3) and radiographic fracture healing in at least three cortices out of four across two imaging planes at 12 weeks postoperatively-and assessing short-term safety by monitoring adverse events, including device-related and serious adverse events.

Secondary assessments focus on postoperative clinical function and wrist range of motion (ROM), measured using a goniometer, as well as radiographic markers of implant biodegradation. Long-term safety is evaluated through the monitoring of potential growth disturbances at 52 and 104 weeks, including limb length discrepancies or growth plate abnormalities.

This early-stage investigation aims to generate clinical data on the application of magnesium-based resorbable implants in pediatric fracture care and to assess their potential to support bone healing without interfering with skeletal development.

Interventions

  • Device Magnesium-based bioresorbable DrillPin for fixation of distal radius fractures in children
    This is a first-in-child clinical investigation of a bioresorbable magnesium alloy DrillPin (RemeOs™) for fixation of distal radius fractures in children aged 5 to \<14 years. The implant is investigational, not CE-marked or FDA-approved, and represents a novel alternative to traditional metallic implants. It gradually degrades in vivo, eliminating the need for removal. The study focuses on safety and feasibility in a pediatric population, supported by preclinical data from a similar Mg-based Re

Primary outcome measures

  • Number of participants with pain score <3 on the FACES® Pain Rating Scale (criterion of successful implantation) [Time frame: At 12 weeks postoperatively]
  • Number of participants with radiographic healing in at least 3 of 4 cortices on two-plane radiographs (criterion of successful implantation) [Time frame: At 12 weeks postoperatively]
  • Number of participants with at least one adverse event (AE), adverse device effect (ADE), serious adverse event (SAE), or serious adverse device effect (SADE) [Time frame: From day of surgery through 12 weeks postoperatively]
Secondary outcome measures (2)
  • Passive wrist range of motion (ROM) in degrees measured to assess functional recovery [Time frame: 2, 4, 6 (optional), 12, 26, 52, and 104 weeks postoperatively]
  • Number of participants with radiographic evidence of growth disturbance (growth arrest or length discrepancy) [Time frame: At 52 and/or 104 weeks postoperatively]

Eligibility criteria

Inclusion criteria

  • Distal Radius Fractures
  • Written informed consent of the parent, oral agreement of the patient documented as informant consent of the child
  • Subject and parents have been informed of the nature of the study, agrees to participate and parent signs the approved consent form. • Female patients in childbearing age (female patients who have begun menstruation) perform a pregnancy test prior inclusion

Exclusion criteria

  • Pathological bone lesions (e.g. bone cyst or osteomyelitis)
  • Underlying diseases (kidney diseases, uncontrolled diabetes mellitus)
  • Polytraumatized patients
  • Suspicion of child abuse
  • Inability or unwillingness to give informed consent
  • Multiple fracture (excluding associated ulna fracture)
  • Open Fracture
  • Pregnancy (tested in all female patients who have begun menstruation)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Publications

  • Grun NG, Holweg PL, Donohue N, Klestil T, Weinberg AM. Resorbable implants in pediatric fracture treatment. Innov Surg Sci. 2018 May 29;3(2):119-125. doi: 10.1515/iss-2018-0006. eCollection 2018 Jun. PMID 31579775
  • Sturznickel J, Delsmann MM, Jungesblut OD, Stucker R, Knorr C, Rolvien T, Kertai M, Rupprecht M. Safety and performance of biodegradable magnesium-based implants in children and adolescents. Injury. 2021 Aug;52(8):2265-2271. doi: 10.1016/j.injury.2021.03.037. Epub 2021 Mar 18. PMID 33775413
  • Ramoutar DN, Shivji FS, Rodrigues JN, Hunter JB. The outcomes of displaced paediatric distal radius fractures treated with percutaneous Kirschner wire fixation: a review of 248 cases. Eur J Orthop Surg Traumatol. 2015 Apr;25(3):471-6. doi: 10.1007/s00590-014-1553-6. Epub 2014 Oct 21. PMID 25331168
  • Holweg P, Berger L, Cihova M, Donohue N, Clement B, Schwarze U, Sommer NG, Hohenberger G, van den Beucken JJJP, Seibert F, Leithner A, Loffler JF, Weinberg AM. A lean magnesium-zinc-calcium alloy ZX00 used for bone fracture stabilization in a large growing-animal model. Acta Biomater. 2020 Sep 1;113:646-659. doi: 10.1016/j.actbio.2020.06.013. Epub 2020 Jun 14. PMID 32553919

Identifiers

NCT: NCT07028541 · 243-03-CI-02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗